Marijuana Natural Plant Cures Cancer! Legalize Cannabis! BBC Horizon: UK Medicinal Pharma Hypocrisy
Rating: 0.0/5 (0 vote cast)
BBC Horizon A Look At Medicinal Cannabis & Sativex UK Cannabidiol (CBD) in Industrial Hemp: Eli Lilly Cannabis: http://goo.gl/mwBvI "A look at the development of SATIVEX, the cannabis derived medicine being grown at the secret location known as Porton Down. Only now was the existence of CBD (Cannabidiol) and its anti-psychotic properties mentioned, and the claim made that some of the newer recreational strains contain no CBD at all (which isnt actually correct, although CBD levels are low in some strains). A good case for the proper regulation of the commercial trade was almost made, but avoided." The UKCIA News Blog http://ukcia.org/wordpress/?p=53 video http://goo.gl/xvQ9V GW Pharmaceuticals http://www.gwpharm.com/ http://www.bbc.co.uk/programmes/b00hhmd1 Cannabidiol (CBD) in Industrial Hemp Google doc http://goo.gl/k0Wey http://www.showmethefacts.org/medical-marijuana-facts/cannabidiol/ GW files new regulatory application to expand Sativex® approvals to additional European countries 22 November 2011 Porton Down, UK; 22 November 2011: GW Pharmaceuticals plc (AIM: GWP) today announces that it has submitted an application under the European Mutual Recognition Procedure (MRP) to seek to expand the marketing authorization for Sativex® to a number of additional European member states. Porton Down, UK; 22 November 2011: GW Pharmaceuticals plc (AIM: GWP) today announces that it has submitted an application under the European Mutual Recognition Procedure (MRP) to seek to expand the marketing authorization for Sativex® to a number of additional European member states. The new MRP follows successful completion of a previous MRP earlier this year in which recommendation for approval of Sativex® was obtained from regulatory authorities in Germany, Italy, Denmark, Sweden, Austria and the Czech Republic. Prior to this, Sativex® received approval in 2010 in the UK and Spain. The complete list of countries to which the MRP application is being made is currently being finalized. The list is expected to include approximately ten new countries and will mean that if this MRP process is successful, approaching twenty European countries will have recommended approval of Sativex. It is expected that this new MRP process should complete around mid 2012. As with the previous MRP, the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), is acting as Reference Member State for the purposes of this new MRP procedure. Dr Stephen Wright, GW's R&D Director, said, "This new regulatory filing seeks to build on our regulatory successes to date by expanding the approval of Sativex® to several additional European markets. We look forward to progressing this application during the first half of next year." Sativex® oromucosal spray is a first in class endocannabinoid system modulator for the treatment of spasticity in MS. Sativex® has been developed by UK-based GW Pharmaceuticals and is marketed in Europe (except the UK) by Almirall, S.A. Sativex® is approved in the UK, Spain, Germany, Denmark, Czech Republic, Canada and New Zealand as a treatment of MS spasticity. The product is also in Phase III clinical development as a treatment for cancer pain. Enquiries: GW Pharmaceuticals plc (Today) + 44 20 7831 3113 Dr Geoffrey Guy, Chairman (Thereafter) + 44 1980 557000 Justin Gover, Managing Director FTI Consulting + 44 20 7831 3113 Ben Atwell / John Dineen Peel Hunt LLP +44 207 418 8900 James Steel / Vijay Barathan Notes to Editors About GW GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including development and regulatory clearance of the GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex®and other products by consumer and medical professionals. http://goo.gl/m2BiU
Added on Mar 16, 2012 by DeekJackson
Video Responses (0)
Be the first to post a video response!